Sorry, you need to enable JavaScript to visit this website.

All announcements

Announcement Date

EMBEDA® discontinuation


As of November 15, 2019, Pfizer discontinued sale of all EMBEDA® extended-release capsules. This decision was not made because of any safety or efficacy issues, or because of manufacturing concerns. Patients should talk to their healthcare provider about other appropriate treatment options.
March 31, 2020

Pfizer Shares Safety Data on Azithromycin-Hydroxychloroquine Combination


On March 25, 2020 Pfizer Inc. followed up on the recently made commitment to share data and knowledge as part of our five-point plan to battle the COVID-19 pandemic.
March 30, 2020

Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine

March 24, 2020

US FDA Approves sNDA for Expanded Indication of Eucrisa in Children as Young as 3 Months of Age with Mild to Moderate Atopic Dermatitis


US FDA Approves sNDA for Expanded Indication of Eucrisa in Children as Young as 3 Months of Age with Mild to Moderate Atopic Dermatitis
March 24, 2020

Pfizer Outlines Five-Point Plan to Battle COVID-19


On Friday, March 13, 2020, Pfizer today issued a five-point plan calling on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat COVID-19.
March 16, 2020

Tikosyn Drug Shortage Communication – Supply Status

December 4, 2019

Partner4Better (P4B) Launches!


Pfizer Medical Information is pleased to announce the launch of the Partner4Better (P4B) global microsite where healthcare professionals (HCPs) have access to 5 educational modules- Medical Information, Counterfeits, Health Literacy, Medication Adherence and Literature Searching. Click here to access: https://www.partner4better.com/.
October 10, 2019

VYNDAQEL® OR VYNDAMAX™ Dose Conversion Tool


This tool was designed to help with VYNDAQEL® OR VYNDAMAX™ dose conversion.
September 13, 2019